Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG: Ibrutinib

Sponsor

Pharmacyclics LLC.

Collaborators

[object Object]